Granata Bio concludes screening in Phase III GRACE trial for IVF
Granata Bio has completed participant screening in its Phase III GRACE trial of Granata Bio human menopausal gonadotropin (GB-hMG) in…
23 Oct 2026
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m). The financial package…
22 Oct 2026
Edwards secures FDA approval for tricuspid valve repair system
The US Food and Drug Administration (FDA) has approved Edwards Lifesciences’ tricuspid valve repair system, PASCAL Precision. The transcatheter medical device is indicated to improve functional status and quality of…
22 Oct 2026
Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
The US Food and Drug Administration (FDA) has authorised Lynch Regenerative Medicine’s investigational new drug (IND) application for a Phase II study of injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB)…
22 Oct 2026
MSD’s Keytruda and Padcev combination receives EC approval
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults. The clearance permits…
21 Oct 2026
Abbott secures CE Mark for Cologuard Plus cancer test
Abbott has secured CE Mark approval under the EU’s In Vitro Diagnostic Medical Devices Regulation (IVDR) for its Cologuard Plus colorectal cancer screening test. The regulatory clearance enables the company…
21 Oct 2026
AstraZeneca and Oracle collaborate to test AI in clinical trial recruitment
AstraZeneca and Oracle have signed a non-binding agreement to investigate how AI and real-world data can help medical teams recruit eligible candidates for clinical trials. The initiative aims to address…